ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

Group 1 - ProKidney Corp. is a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD) [1] - The CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [2] - ProKidney's lead product candidate, rilparencel (REACT), is a first-in-class autologous cell therapy aimed at preserving kidney function in patients with advanced CKD and type 2 diabetes [3] Group 2 - The ongoing Phase 3 REGEN-006 (PROACT 1) study is evaluating the potential of rilparencel to improve kidney function [3] - ProKidney was founded in 2015 after a decade of research in cell therapy for CKD [3] - The live webcast of the presentation will be accessible through ProKidney's website, with a replay available for 30 days post-event [2]